ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)

被引：0
|
作者：
Griguolo, G. [1 ]
Braso-Maristany, F. [2 ]
Pascual, T. [3 ]
Chic, N. [4 ]
Vidal, M. [4 ]
Adamo, B. [4 ]
Giarratano, T. [1 ]
Dieci, M. V. [5 ]
Guarneri, V. [5 ]
Prat, A. [2 ]
机构：
[1] Ist Oncol Veneto IRCCS, Med Oncol 2, Padua, Italy
[2] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain
[3] SOLTI Breast Canc Cooperat Grp, Barcelona, Spain
[4] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[5] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Mechanisms of action and resistance to anti-HER2 antibody-drug conjugates in breast cancer
    Saleh, Khalil
    Khoury, Rita
    Khalife, Nadine
    Chahine, Claude
    Ibrahim, Rebecca
    Tikriti, Zamzam
    Le Cesne, Axel
    CANCER DRUG RESISTANCE, 2024, 7 : 2 - 15
  • [2] HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
    Alberto Ocaña
    Eitan Amir
    Atanasio Pandiella
    Breast Cancer Research, 22
  • [3] HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
    Ocana, Alberto
    Amir, Eitan
    Pandiella, Atanasio
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [4] Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates
    Wong, Deborah J. L.
    Hurvitz, Sara A.
    ANNALS OF TRANSLATIONAL MEDICINE, 2014, 2 (12)
  • [5] Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
    Zhang, Xinling
    Huang, Andrew C.
    Chen, Fahai
    Chen, Hu
    Li, Lele
    Kong, Nana
    Luo, Wenting
    Fang, Jianmin
    ANTIBODY THERAPEUTICS, 2022, 5 (01) : 18 - 29
  • [6] Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer
    Chai, Mengting
    Li, Li
    Wu, Huachao
    Liu, Yue
    Yi, Zongbi
    Yu, Haijun
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 195
  • [7] Comparative analysis of anti-HER2 antibody-drug conjugates in tumor spheroid models
    McBain, Kirsty
    Barnes, Kalpana
    Bevan, Nicola
    CANCER RESEARCH, 2024, 84 (06)
  • [8] Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer
    Shah, Chirayu
    Miller, Todd W.
    Wyatt, Shelby K.
    McKinley, Eliot T.
    Olivares, Maria Graciela
    Sanchez, Violeta
    Nolting, Donald D.
    Buck, Jason R.
    Zhao, Ping
    Ansari, M. Sib
    Baldwin, Ronald M.
    Gore, John C.
    Schiff, Rachel
    Arteaga, Carlos L.
    Manning, H. Charles
    CLINICAL CANCER RESEARCH, 2009, 15 (14) : 4712 - 4721
  • [9] Antibody-drug conjugates in HER2-positive breast cancer
    Li Lixi
    Zhang Di
    Liu Binliang
    Lv Dan
    Zhai Jingtong
    Guan Xiuwen
    Yi Zongbi
    Ma Fei
    中华医学杂志英文版, 2022, 135 (03) : 261 - 267
  • [10] Antibody-drug conjugates in HER2-positive breast cancer
    Li, Lixi
    Zhang, Di
    Liu, Binliang
    Lv, Dan
    Zhai, Jingtong
    Guan, Xiuwen
    Yi, Zongbi
    Ma, Fei
    CHINESE MEDICAL JOURNAL, 2022, 135 (03) : 261 - 267
12345